Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.

abstract：:The incidence of renal cell cancer is increasing and surgery is the only curative treatment for patients presenting with localized disease at diagnosis. The treatment of metastatic renal cell cancer is palliative and, until recently, immunotherapy has been the standard treatment approach with response rates between 10...

journal_title：Expert review of anticancer therapy

authors： Gore ME,Harrison ML,Montes A

更新日期：2007-01-01 00:00:00

abstract：:Treatment options for patients have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Owing to the promising activity seen with lenalidomide in the relapsed/refractory setting, its use has now expanded to induction and maintenance therapy. ...

journal_title：Expert review of anticancer therapy

authors： Sirohi B,Powles R

更新日期：2009-11-01 00:00:00

abstract：:Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

journal_title：Expert review of anticancer therapy

authors： Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

更新日期：2006-06-01 00:00:00

abstract：:Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O,Alorabi M

更新日期：2015-01-01 00:00:00

abstract：:Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

journal_title：Expert review of anticancer therapy

authors： Gulley J,Dahut WL

更新日期：2005-04-01 00:00:00

abstract：INTRODUCTION:The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worseni...

journal_title：Expert review of anticancer therapy

authors： Donini M,Buti S,Massari F,Mollica V,Rizzo A,Montironi R,Bersanelli M,Santoni M

更新日期：2020-06-01 00:00:00

abstract：:Introduction: Surgical treatment of thyroid cancer has become less aggressive but for many patients, the threshold for performing total thyroidectomy (TT), as opposed to thyroid lobectomy (TL), has remained unclear. Current American Thyroid Association (ATA) guidelines encourage more individualization of treatment opt...

journal_title：Expert review of anticancer therapy

authors： Guo MY,Wiseman JJ,Wiseman SM

更新日期：2020-12-15 00:00:00

abstract：:Introduction: Colorectal cancer (CRC) is one of the most important health problems in the Western world. In order to reduce the burden of the disease, two strategies are proposed: screening and prompt detection in symptomatic patients. Although diagnosis and prevention is mainly based on colonoscopy, faecal haemoglobi...

journal_title：Expert review of anticancer therapy

authors： Gallardo-Gómez M,De Chiara L,Álvarez-Chaver P,Cubiella J

更新日期：2021-01-28 00:00:00

abstract：:Until recently, cytokine therapy has been the only validated option for patients with advanced renal cancer. IFN-alpha is one of very few treatments that have demonstrated improved median survival compared with the appropriate control. In patients with synchronous metastases at diagnosis, debulking nephrectomy prior t...

journal_title：Expert review of anticancer therapy

authors： Coppin C

更新日期：2008-06-01 00:00:00

abstract：:Cancer cells become dangerous when they acquire the ability to invade through physical barriers in the body and disseminate to distant sites. Recent evidence has demonstrated that cancer cells utilize specialized structures called invadopodia, unique protrusions that concentrate proteases such as matrix metalloprotein...

journal_title：Expert review of anticancer therapy

authors： Stoletov K,Lewis JD

更新日期：2015-01-01 00:00:00

abstract：:Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

journal_title：Expert review of anticancer therapy

authors： Reed AB,Parekh DJ

更新日期：2010-01-01 00:00:00

abstract：:The annual conference of the International Society for Biological Therapy of Cancer (iSBTc), recently renamed the Society for Immunotherapy of Cancer (SITC), provides clinicians and scientists with a uniquely broad yet focused view of the growing field of tumor immunology and cancer immunotherapy. In this time of exci...

journal_title：Expert review of anticancer therapy

authors： Kotlan B,Balwit JM

更新日期：2011-03-01 00:00:00

abstract：:Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

journal_title：Expert review of anticancer therapy

authors： Ghavamian R,Hakimi AA

更新日期：2009-12-01 00:00:00

abstract：:It has been evident for some time that individuals from some families exhibit a genetic predisposition to breast cancer. Since the discovery of the first breast cancer susceptibility gene, BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led to the ide...

journal_title：Expert review of anticancer therapy

authors： Ahmed M,Lalloo F,Evans DG

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:Immunotherapy has emerged as a major class in the therapeutic arsenal of multiple myeloma. Cell-based immunotherapy (CAR T-cells) and monoclonal antibody-based immunotherapy (naked monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers) are the two cornerstones of this novel approa...

journal_title：Expert review of anticancer therapy

authors： Jullien M,Touzeau C,Moreau P

更新日期：2020-10-26 00:00:00

abstract：:A large number of different 5-hydroxytryptamine (HT)(3) receptor antagonists have been marketed with the indication of preventing nausea and vomiting induced by chemotherapy--palonosetron is the most recently developed of these. Pharmacologic studies have revealed that palonosetron has a long half-life, a high affinit...

journal_title：Expert review of anticancer therapy

authors： Ruhlmann C,Herrstedt J

更新日期：2010-02-01 00:00:00

abstract：INTRODUCTION:: Renal cell carcinoma is no longer considered a monolithic disease, but a group of different entities exhibiting unique molecular alterations requiring a tailored systemic approach. One of the remaining challenges is the identification of the best candidate for a particular therapeutic regimen. AREAS COV...

journal_title：Expert review of anticancer therapy

authors： González J,Gaynor JJ,Ciancio G

更新日期：2021-01-29 00:00:00

abstract：INTRODUCTION:Germ cell tumors (GCTs) are the most common solid malignancies in young men. The overall cure rate of GCT patients in metastatic stage is excellent, however; patients with relapsed or refractory disease have poor prognosis. Attempts to treat refractory disease with novel effective treatment to improve prog...

journal_title：Expert review of anticancer therapy

authors： Kozakova K,Mego M,Cheng L,Chovanec M

更新日期：2020-11-02 00:00:00

abstract：:Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic respon...

journal_title：Expert review of anticancer therapy

authors： Bartsch G,Mitra AP,Cote RJ

更新日期：2010-12-01 00:00:00

abstract：:Pegylated liposomal doxorubicin (PLD) was first approved for platinum-refractory ovarian cancer in 1999 and then received full approval for platinum-sensitive recurrent disease in 2005 by the US FDA. PLD remains an important therapeutic tool in the management of recurrent ovarian cancer in 2012. Phase-II and III clini...

journal_title：Expert review of anticancer therapy

authors： Rakowski JA,Ahmad S,Holloway RW

更新日期：2012-01-01 00:00:00

abstract：:Novel targeted agents, such as VEGF receptor-tyrosine kinase inhibitors (VEGFR-TKIs) and mTOR inhibitors, have improved therapy for metastatic renal cell carcinoma. Sequential administration of agents with similar mechanisms of action has shown some efficacy in small retrospective studies; however, prospective Phase I...

journal_title：Expert review of anticancer therapy

authors： Larkin J,Swanton C,Pickering L

更新日期：2011-04-01 00:00:00

abstract：:Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamo...

journal_title：Expert review of anticancer therapy

authors： Bria E,Carlini P,Cuppone F,Vaccaro V,Milella M,Cognetti F

更新日期：2010-08-01 00:00:00

abstract：:Estrogens are involved in numerous physiological processes and have crucial roles in certain disease states, such as mammary carcinomas. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is found in breast tissue and the i...

journal_title：Expert review of anticancer therapy

authors： Brueggemeier RW

更新日期：2002-04-01 00:00:00

abstract：:miRNAs, which are small single-stranded RNA molecules composed of 18-23 nts, act as oncogenes or tumor suppressor genes playing important roles in the processes of tumor formation, infiltration and metastasis. Lung cancer currently has the highest morbidity and mortality among all malignant tumors; yet, lack of early ...

journal_title：Expert review of anticancer therapy

authors： Jiang C,Hu X,Alattar M,Zhao H

更新日期：2014-04-01 00:00:00

abstract：:Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...

journal_title：Expert review of anticancer therapy

authors： Shapiro D,Tareen B

更新日期：2012-07-01 00:00:00

abstract：:Background: This evaluation emphasizes the main points of the original article 'Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies' by Sprenger et al. and provides further justification for the use of an alternative approach in the design...

journal_title：Expert review of anticancer therapy

authors： Roussos Torres ET,Epstein AL

更新日期：2021-01-19 00:00:00

abstract：:Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

journal_title：Expert review of anticancer therapy

authors： Kortmann RD

更新日期：2014-01-01 00:00:00

abstract：:Androgen receptor (AR) signaling is necessary for the development of prostate cancer. Androgen-deprivation therapy (ADT) for prostate cancer was described over 50 years ago and ADT remains the mainstay of systemic therapy. AR signaling remains intact as the disease evolves to castration-resistant prostate cancer (CRPC...

journal_title：Expert review of anticancer therapy

authors： Taplin ME

更新日期：2008-09-01 00:00:00

abstract：:Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

journal_title：Expert review of anticancer therapy

authors： Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

更新日期：2012-06-01 00:00:00

abstract：:Therapeutic outcomes of the currently used chemotherapeutic agents for recurrent or advanced head and neck squamous cell carcinoma, such as methotrexate or a combination of 5-fluorouracil and cisplatin, are far beyond satisfaction. New chemotherapeutic agents, such as taxanes, paclitaxel and docetaxel, are among the m...

journal_title：Expert review of anticancer therapy

authors： Kim KB,Khuri FR,Shin DM

更新日期：2001-06-01 00:00:00